Azelto Capsule

Naftidrofuryl oxalate possesses a 5HT2-blocking activity and counteracts both the vasoconstrictor effect and the effect promoting platelet aggregation due to serotonin. Naftidrofuryl oxalate has a direct effect on intracellular metabolism. Thus it increases ATP level, decreases lactic acid level in ischemic conditions and enhances the cellular oxidative capacity. Also, Naftidrofuryl oxalate is a powerful spasmolytic agent.

One or two Naftidrofuryl oxalate capsules three times daily during meals for a minimum of three months or at the discretion of the physician.

Hypersensitivity to the active substance or to any of the excipients. Patients with a history of hyperoxaluria or recurrent calcium-containing kidney stones.

• Gastrointestinal disorders (uncommon): Diarrhoea, nausea, vomiting and epigastric pain.
• Renal and urinary disorders (very rare): Calcium oxalate kidney stones.
• Skin and subcutaneous tissue disorders (uncommon): Skin rash.
• Hepatobiliary disorders (rare): Liver damage.

In the absence of any relevant clinical data, the use of Naftidrofuryl Oxalate is not advisable during pregnancy. In the absence of specific data concerning the excretion of the drug in human milk, Naftidrofuryl Oxalate should not be used by breastfeeding women.

The administration of Azelto may modify the composition of the urine, promoting the formation of calcium oxalate kidney stones. The administration of Azelto without liquid before going to bed may cause local oesophagitis. Therefore, it is essential to always take the capsule with a sufficient amount of water. Cases of liver damage have been reported.

Depression of cardiac conduction and convulsions may occur.

5-HT Agonists

Store below 25°C. Protect from light & moisture. Keep the medicine out of reach of children.